

Leading the Future with New Biotechnology

**iONEBIO Inc.**




**Hidden Hero**



#1007~1012, Seongnam central biz tower 314, Galmachi-ro,  
Jungwon-gu, Seongnam-si, Gyeonggi-do, Republic of Korea  
[www.ionebio.com](http://www.ionebio.com) TEL: 031-360-1210 FAX: 031-360-1220

■ For the healthy future of mankind

**IONE BIO**





## Disclaimer

This data has been prepared by **IONE BIO Inc.** (hereinafter referred to as the "Company") to enhance understanding of the company's business activities and is prohibited from taking out, copying, or redistributing it to others.

The "predictive information" contained in this material is information that has not been individually verified. This is related to future events, not past, which means the company's expected future management status and financial performance, and includes words such as 'expect', 'forecast', 'plan', 'anticipate', '(E)' and so on.

The above "predictive information" is affected by future changes in the business environment, which inherently implies uncertainty, which may result in significant differences in actual future performance from what is stated or implied in "predictive information". Please note that the future outlook is considering the current market situation and the company's management direction, and it can be changed due to changes in the market environment and changes in strategy in the future.

Furthermore, we would like to inform you that the Company and its employees will not be liable for any losses arising from the use of this material (including negligence and other cases).

**Please refrain from unauthorized copying and distribution of this material, which includes corporate secrets.**

Investor Relations

# Contents

Chapter 1	Company Overview	.....	7
Chapter 2	Key Business	.....	23
Chapter 3	Benefits for Shareholders	....	35

## Leading with New Biotechnology **iONEBIO Inc.**

iONEBIO is where creative ideas and talents come together to create the best solutions,  
a company established for a healthy future of mankind.





## Chapter 1

Investor Relations

# Company Overview

- Company Overview
- Company History
- CEO
- Manpower Research
- Shareholder Composition
- Members of iONEBIO



# I want BIO

iONEBIO



No. 1 of K-BIO Industry,  
We become one with BIO, **iONEBIO Inc.**

## Three Engines of Growth

### A. High-Growth Bio-Platform

- New drug development  
(Human peptide based dental bone regeneration)
- Skin regeneration treatment



### B. Profitable Diagnostic Platform

- Diagnostic kit, DNA analysis  
(POCT Molecular diagnosis/Immune diagnosis)



### C. Highly Scalable Optical Platform

- Analysis equipment  
(Precise optical technology/clinical precision technology/optical analysis technology)



# Company Overview

## Company Status

(As of 2021.05)

iONEBIO



Company Name	iONEBIO Inc.
CEO	Min Bae Kim / Young Bok Chung
Founding Date	Jan 2, 2018 (No. of Employees: 31)
Head Office	#1007~1012, Seongnam Central Biz Tower, Galmachi-ro 314, Jungwon-gu, Seongnam-si, Gyeonggi-do, 13201 Republic of Korea
Major Business	Alveolar Bone Treatment (peptide material), Oral Cancer Diagnostic Kit, 3D Intra Oral Scanner, COVID-19 Diagnostic kit, Virus/ Disease Diagnosis Device and Treatment
Capital	\$5,000,000
Website	www.ionebio.com

## Company View

### • Office



### • Laboratory




### • Display & Seminar




### • Product



## Organization



iONEBIO





## Company history

A company that creates the value of K-BIO by putting together healthcare secrets and medical puzzles. iONEBIO has selected three fields "DNA analysis, molecular diagnosis and dental health" that we believe hold the pillars of human health and achieved great results in each field.

### Builders

Pipeline acquisition steps

2018



#### Development of 28 disease risk DNA testing

10 most common cancers, dementia and cardiovascular diseases

#### Development of 3D oral scanner

Prototype completed, using infrared(IR) technology



### Leap

Secured technology transfer/  
Started exporting to overseas

2019~2020



#### Oral cancer test kit technology transferred to Seoul National University, selected as the government innovation project

World's first saliva based oral cancer test kit

#### M&A of healthcare business

Started body posture alignment business

#### Alveolar Bone Treatment

Technology transferred to the College of Dentistry, Seoul National University Joint development with Seoul National University of Korea for the regeneration of the alveolar bone treatment

#### FICS, exported to Asuncion, Paraguay

FICS(Fast Infection Control System) set up at Silvio pettirossi international airport

#### Development of COVID-19 Diagnosis Kit, Export Started to Overseas

Development of iLAMP Novel-CoV19 Detection Kit, started exporting to South America and Africa

## The path we've taken becomes a new path for K-BIO Industry

### Expander

Full-scale development/  
export of treatments

2021



#### Full-scale Development of Alveolar Bone Treatment, Start of Non-clinical Phase

Start of non-clinical stage to determine efficiency and preparation initiated for product licensing

#### Launched Prototypes of Oral Cancer Diagnosis Kit Selected as Government Assignment

Launch of prototypes for the commercialization business in 2021  
Scheduled for clinical trial and licensing in 2022

#### COVID-19 Diagnostic Kit supplied to the International Airport of Paraguay and National Hospital

Following the supply to the International Airport of Paraguay in 2020 Started to supply to Paraguay National Hospital

#### Development Completed and Sales of COVID-19 Neutralized Antibody Kit

Neutralized antibody Kit that can diagnose vaccine antibody formation within 20 minutes.  
(AI-based diagnosis within 5 minutes)





## Min Bae Kim

Founder & CEO

### ‘Taking a Path No One Has Ever Taken Before’

CEO Min Bae Kim, who has a unique history in the industry, started as a working-level staff when he first joined a bio company and became the chief executive officer(CEO) in the shortest time with his excellent sense of business and abilities. And his enthusiasm and momentum played a key role in the company's remarkable growth.

iONEBIO Inc. is the fruit of Minbae Kim who has already proved his leadership in the past, created with his excellent business skills and know-hows.

#### Career

- 2017~Today CEO of iONEBIO Inc.
- 2011~2017 CEO of YD Institute of Biomedical Research

#### Academic Background/Research Achievements

Kyunghee University,  
Department of Architectural Engineering  
Sungkyunkwan University, Masters and PhD.  
of Medicine, Department of Medical Device Industry

- Development of Genetic Analysis Kit for Dentistry
- Development of Oral Cancer Diagnostic Kit
- COVID-19 Diagnostic Kit

#### Awards

- JUL 2019: Grand Prize of Korea Health Industry Award by the Ministry of Health and Welfare
- MAY 2018: Grand Prize of Bio Field by Asian Medical Beauty Association

iONEBIO Inc. will become  
a must-have company that  
contributes to the world.

We aim to become a **global innovative company** with the mission for a healthy future for mankind

## Young Bok Chung

Founder & CEO

### ‘The Healthy Future of K-BIO Industry’

CEO Chung, Yong-bok whose passion for future value development and investment has a big dream for the K-bio market. Especially his knowledge and experience accumulated in the field of dentistry will have the best synergy for creating innovative dental products and technologies. His dream to make the K-Dentistry No.1 globally will come true at iONEBIO, Inc.



#### Career

- Current President of Asian Preventive Dental Association
- Current President of Korea Oral Health Association
- Current Adjunct Professor of Dankook University Dental College
- 2017~Today CEO of iONEBIO Inc.
- 2001~2019 CEO of Dr. Prevent Inc.

#### Academic Background/Research Achievements

PhD. in Dentistry, Dankook University  
• Development of DCS (Dental Care System)

#### Awards

- 2016 : Awarded by the Minister of Health and Welfare
- 1992 : Awarded by the Minister of Health and Welfare

The path iONEBIO Inc.  
takes will be the manual of  
the K-Bio Industry.



## Manpower Research



### Byung moo Min

Head of R&D

Selected as 'World 100 Scientists' by IBC

#### Career

- Professor at Seoul National University, Graduate School of Dentistry (Science and Technology Merit Award)
- 2018 SCI 'International Journal of Oncology' Cover Model
- 2009~2011 resident of the Korean Branch of International Dental Research Association
- 2006~Today Member of the Faculty of Medicine, Korean Academy of Science and Technology
- 2006~2007 President of the Korean Academy of Oral Biology

**Bone Regeneration Peptide Developer**

**Oral Cancer Diagnostic Kit Developer**  
(30years of Oral Cancer Research)

**Dominion of Strong Manpower that Leads the Global Bio Ecosystem**

## Manpower



### Yong Deok Park

Executive Director of R&D

Selected as 'World 100 Scientists' by IBC

#### Career

- 2016~2018 Professor at Chosun University, Graduate School of Dentistry
- 2007~2016 Professor at Kyung Hee University, Graduate School of Dentistry
- 2015~2019 Vice President/President of the Asian Preventive Dentistry Association
- 2015 Prime Minister Award
- General Director of the Korean Oral Health Association
- New Medical Technology Evaluation Committee Chairman of the Dental Field

**Alveolar bone material/ Innovative implant developer**

**Founder of Saliva Bio Research Institute**



### Jun Sik Lee

Executive Director of R&D

#### Career

- 2011~Today Professor, Department of Life Sciences, College of Natural Sciences, Chosun University
- 2011~2012 Evaluation Member of the Food Technology Planning and Evaluation Institute
- 2007~2011 Professor BK in the College of Medicine of Pusan National University
- Senior Researcher of the Agriculture, Forestry and Fisheries Quarantine and Research Division

**Alveolar bone material/ Peptide material developer**


Research on Immune-related Diseases

# 5

Investor Relations

## Shareholders Composition

Issued shares: 10,519,500



Major shareholders (As of 2020.05.21)

Shareholders		Capital Classification	No.of shares	% Ownership
CEO	MB Kim	Ordinary	2,800,000	26.62%
	YB Chung	Ordinary	2,609,625	24.81%
Related person		Ordinary	1,668,000	15.86%
Employees		Ordinary	1,436,300	13.64%
Dentist		Ordinary	1,272,065	12.00%
Others		Ordinary	733,510	6.97%
Total			10,519,500	100.00%

## Advisory Committee

iONEBIO Inc. is characterized by its shareholders and advisory group consisting mostly of dentists and physicians. Among them, the advisory panel will be able to contribute greatly to clinical consulting and technical advice from the development of IONE Bio products. Keymen and accompanying strategists of iONEBIO.

- \*\*\*\*\* Lee : Professor of the College of Dentistry at Asan Hospital (Ulsan University), Judge of New Medical Technology Evaluation, Ministry of Food and Drug Safety
- \*\*\*\*\* Ahn : Professor at the College of Dentistry, Yonsei University, Judge of New Medical Technology Evaluation, Ministry of Food and Drug Safety
- \*\*\*\*\* Lee : Professor at the College of Dentistry, Seoul National University, Judge of New Medical Technology Evaluation, Ministry of Food and Drug Safety
- \*\*\*\*\* Shin : Professor at Dankook University School of Dentistry, former president of the Asian Society of Preventive Dentistry
- \*\*\*\*\* Kim : Former President of the Korean Dental Association
- \*\*\*\*\* Jeong : President of Korea Oral Health Association
- \*\*\*\*\* Kim : President/Chair of the Department of Dentistry
- \*\*\*\*\* Maeng : Professor at Dankook University's College of Dentistry, Current President/Chair of Gaon Dental Association
- \*\*\*\*\* Hwang : Executive Officer of the Korean Dental Association, Currently an adjunct professor at Seoul National University College of Dentistry
- \*\*\*\*\* Lee : Executive Officer of the Korean Dental Association, Current Executive Officer of the Seoul Dental Association
- \*\*\*\*\* Lee : President of Incheon Dental Association
- \*\*\*\*\* Lim : Vice-Chairman of Incheon Dental Association
- \*\*\*\*\* Lee : Vice-Chairman of Incheon Dental Association
- \*\*\*\*\* Shin : Executive of Incheon Dental Association
- \*\*\*\*\* Kim : Representative director of Yonsei Goun Smile Dental Clinic
- \*\*\*\*\* Choi : President of the Korean Society of Sedentary Medicine, Executive Director of Korean Neurosurgical Society
- \*\*\*\*\* Jeon : Adjunct Professor, College of Dentistry, Dankook University
- \*\*\*\*\* Lee : Current Director of Raon Dental Group Hospital




**We carry out our work in cooperation with the Advisory Committee composed of the best dentists/doctors**

## 6

Investor Relations

## Members of iONEBIO

iONEBIO's executives and employees are composed of experts in various fields to grow on the global stage, such as bio-related master's and doctoral degrees, management, overseas business, and marketing.



## #Research and development (R&amp;D)

## Creating a healthy future and new values!

Based on our technical manpower in specialized fields, we are continuing to research for the development of medical devices and treatments. As a result, we are successfully entering the domestic and overseas medical device markets, such as in vitro diagnostic medical devices (immunological diagnosis, molecular diagnosis), dental devices, and peptide treatments. Even now, iONEBIO researchers are creating new values as the best R&D specialized centers based on accumulated research results such as various cancers and infectious diseases.



## #Overseas Business&amp;Marketing

## Overseas Business | Benefits of being bilingual!

They strategically expand the customers by understanding each country's situation and culture. They are the fastest and dynamic members who will lead iONEBIO Inc. to become a Global Company.

## Marketing | iONEBIO's Creative Creator!

They are strategists and coordinators who constantly seek to achieve the best commercial qualities. They have gathered talented people who will make iONEBIO Inc. shine the most with their special senses.

For the healthy future of mankind  
**iONEBIO**

## The best talented people are making the History of iONEBIO



## #Domestic Business

## iONEBIO's Sales Master Team that shows their hard and soft skills when it comes to working at the same time!

Based on the expertise in BIO healthcare, we will become the No.1 in the sales world that sincerely approaches customers through new market development and shared growth with medical clients.



## #Management Team/ Dentistry Business

## Management Team | iONEBIO's Responsible Value-Up Team!


Builds a systematic, efficient and enjoyable work environment by applying the latest smart system and create a positive organizational culture to align with corporate values. Responsible for overall business of creating an organization such as management strategy planning and execution, evaluation, human resources and accounting.

## Dentistry Business | Newly Renewed Dental Brands!

Passionate experts who promote oral products and dental medicines from planning to development and production. Excellent team full of know-hows that maintains a young mind while being seasoned professional based on a long career.

## Organization





## Chapter 2

Investor Relations

### Key Business

- COVID-19 Test Kit
- Oral Cancer Diagnosis Kit
- Alveolar Bone Treatment
- 3D Intra Oral Scanner
- Other Business



# COVID-19 Test Kit

Patent No. 10-2109196

## COVID-19 Test Kit, Achievements of Overseas Exports

### International Airport Installation with Recognized Technology Abroad

- ① iLAMP Novel-CoV19 Detection Kit
- ② iLAMP Novel-CoV19 Detection Kit Plus



### Benefits of using iONEBIO's RT-LAMP PCR Kit

Technological Comparison	RT LAMP PCR	Current RT PCR	Antibody/Antigen
1. Test target	Nucleic Acid(RNA)	Nucleic Acid(RNA)	Finger-prick/Nasopharyngeal
2. Analysis time	Within 25 min ✓	2hours ✗	Within 15 min ✓
3. Accuracy	99% ✓ (High Speed, High Accuracy)	99% ✓ (Low speed, High Accuracy)	60~80% ✗ (High Speed, Low Accuracy)

### Major Achievements

iONEBIO's diagnostic kits and the FICS (Fast Infection Control System)

started to be exported to Silvio Pettrossi International Airport in Paraguay!

2020. August Paraguay



### Major Achievements in Paraguay

1. First COVID-19 test kit approved for use in Paraguay
2. MOU agreement with Ministry of Health of Paraguay
3. MOU for development of Zika virus, Malaria test kit
4. World's first 1-hour fast infection control system installed at the airport
5. Medical examination for 1,260 people per day

### Neutralized Antibody Test Kit



Vaccine/neutralized antibody test kit supply contract in progress of 5 million kits. Preparation for export of the Neutralized Antibody Test Kit to South America, Southeast Asia, the Middle East, and Europe.

→ Expected to be over \$10,000,000 (contracts in progress)

### Neutralized Antibody Test Kit + Vaccine Supply Contract

### Comparison chart/table of share price trends in the same industry



<Seegene Stock Price Chart>



<Osang Healthcare Stock Price Chart>

Looking at the share price trend of COVID-19 Test Kit, Seegene (KOSDAQ public company) and Osang Healthcare (K-OTC public company), has increased more than 10 times compared to the beginning of the year. iONEBIO is a company that have long-term growth potential not only by exporting COVID-19 Test kits to overseas, but also by having a secured additional momentum such as Oral Cancer Diagnostic Kits, Alveolar Bone Treatments, and 3D Intra Oral Scanner.

### Comparison of stock prices in the same industry

Company Name	19.10.7	20.10.5	Remarks
Seegene Inc. (KOSDAQ public company)	KRW 20,700	KRW 299,400	About 14.5 times ↑ Current diagnostic kit main business
Osang Healthcare Co. Ltd. (K-OTC public company)	KRW 186	KRW 85,628	About 460 times ↑ Current diagnostic kit main business
iONEBIO Inc. (Non-listed company)	KRW 5,000	?	Long-term rising momentum, including oral cancer diagnostic kits and alveolar bone treatments other than COVID-19



# Oral Cancer Detection Kit

Patent No. 10-2091483

The only oral cancer detection kit in the world,  
selected as an innovative government project

✳️ **Technological Advantage -**  
The only technology capable of early diagnosis for all oral cancers!




Squamous cell cancer, salivary gland cancer, sarcoma, lymphoma, melanoma, etc.



## Existing Technology

- ① Early diagnosis product for oral cancer commercialized in Korea
- ② Two overseas products have low specificity for oral cancer and have diagnostic limitations (only HPV virus is diagnosed)

Oral Cancer Related Product Comparison Table


Domestic	Overseas	
 <p><b>iONEBIO's first Oral cancer early diagnosis kit in the world</b></p> <p>Diagnosis kit with high specificity and sensitivity by using 3 types of biomarkers capable of <b>early diagnosis of oral cancer</b></p>	 <p>HPV virus-related protein (CD44) has diagnostic limitations with low specificity (50%) using one marker</p>	 <p>Only one marker of HPV virus-related protein is used and it is difficult to apply on-site diagnosis as it takes about 2~3hours</p>

## Necessity of Oral Cancer Detection Kit


### Difficulty of early detection

Oral cancer is easy to misunderstand as stomatitis because it has a similar shape of inflammation to stomatitis. Oral cancer can be treatable if it is detected early, but there are many cases of death due to missed treatment period. The growth rate is getting faster every year, and there are no proper dental diagnostic kits. The cost of treatment for oral diseases and oral cancer is also increasing.

▼ Stomatitis (above)  
Oral cancer (below)



▼ Increasing trend of oral cancer patients



The oral cancer diagnosis that has not been conquered so far,  
iONEBIO with Seoul National University College of Dentistry will make sure to do it.

## Development Schedule

2020	2021	2022
Biomarker Discovery Antibody test/ Patent applicatoin	Antibody production and sample manufacturing Clinical Trials/5Thesis KFDA Approval	Clinical Trials/5Thesis KFDA Approval New medical technology evaluation Product Launching

## Technology Comparison


Current Test Kit vs. iONEBIO's Test Kit	
Current Detection Method	New Product
Invasive (Blood, Biopsy) High-cost (CT, MRI, PET etc)	<b>Non-invaisve(Saliva)</b> Low-cost (rapid kit)
<ul style="list-style-type: none"> <li>• Infection problem</li> <li>• Burden for patients</li> <li>• Difficulty in early diagnosis</li> <li>• Expensive</li> </ul>	<ul style="list-style-type: none"> <li>• No infection</li> <li>• No psychological burden</li> <li>• <b>Early diagnosis possible</b></li> <li>• Low-cost</li> </ul>

# Alveolar Bone Treatment

Patent No. 10-2016-0075873


## Alveolar bone treatment, Achieve a revolution in alveolar bone regeneration

Remarkable effect on the perception of dentistry



In-vivo experiments **demonstrate the bone regeneration effect** of our VnP-16 peptide to BMP-2 level. Along with bone regeneration effect, **bone absorption reduction effect is much better than BMP-2. (Dual Action Effect)**

## The need for Alveolar Bone Treatment



When alveolar bone is damaged, synthetic or autogenous bone + BMP (Emdogain) treatment is available. However, the existing treatment cost is expensive and the regeneration effect is low because it is at a level that slows bone resorption. Once the alveolar bone is lost, it cannot be recovered or regenerated. iONEBIO's alveolar bone treatment can be used in a variety of ways as a material for alveolar bone treatment (bone regeneration treatment), implant coating, and oral products due to the aggregate effect of VnP-16 peptide.

### Benefits of VnP-16 Peptide

- Efficacy** : Excellent effect of inhibiting bone regeneration and bone resorption compared to existing BMP-2
- Economical** : Low production cost compared to BMP-2 due to amino acid synthesis
- Stability** : Excellent stability of formulation (liquid, powder, coating)
- Usability** : expandable to various fields

### Proven performance, key features

- Demonstrate the safety** of Human Peptide
- Significant efficacy demonstrated through in vitro and in vivo experiments
- Patent registration completed in the United States, Europe, and Korea**: Easy to enter the global market as well as in South Korea

### Periodontal disease market to continue to increase in the future

Statistics by the Health Insurance Review and Assessment Service in 2019

**No.1** common disease in Korea: 16,730,985

Treatment cost: More than \$1,500,000,000

In North America, the periodontal disease market is expected to **increase by more than 45%** by 2024.

## MOU with Seoul National University

November 06, 2020 Seoul  
National University Siheung Campus,  
Business Agreement Ceremony  
for Mutual Research Cooperation



## Future Plans



# 3D Intra Oral Scanner

Patent No. 10-2018-0082794

## Beyond the Visible, Dream of invisible optics



✱✱ A new paradigm to the dental industry

### Development completed of Core Element Technology

- Completed liquid lens control and drive technology (in collaboration with Swiss company) for ultra-fast Auto Focus
- Android latest OS 9.0 Pie (ver. 28) Porting success
- Development completed of the world's first 3D 360-degree Real 4 Camera (using MIPI)
- Development completed of wireless BT 5.0, WIFI communication engineering



▲ 3D rendering image



Scan inside the gum


### Third-party oral scanner

- Low speed, low quality
- Fan Noise
- Large size and inconvenient grip
- Imaging distortion
- Price: High price of \$30,000~\$50,000

### 3D Intra Oral Scanner

- **Shortest scan time(1min)**
- **Accurate** scan
- **No fan** noise
- Small size, easy grip
- No image distortion

## Patent technology



### 3D overlay technology

3D overlay technology is an innovative technology that has not existed in the dental market as it projects fixed implant fixture locations into the gums with a 3D oral scanner and can be visually verified without a scan photo.



3D Depth Map




All in One Focus

### ALL IN ONE FOCUS

Unlike the conventional oral scanners, it is possible to take full-length photographing without distortion.

## Development Schedule



## Additional patent applications

### Additional patent application to secure competitive advantage

- |   |   |
|---|---|
| • Reduced light reflection project and image acquisition method | • Method for image splicing                       |
| • Pollution control devices and detachables devices             | • Method for correcting distorted image           |
| • High-speed 3D image acquisition method                        | • Method for extracting 3D meta information       |
|   | • Method for wired/wireless communication devices |




## Dr. Gen Genetic Test (Analysis report for total 28 diseases)



Dr.Gen genetic test is for analyzation and prediction of the risk of getting a particular disease in the future through the DNA inherited from parents. Unlike the medical examination that diagnoses one's current disease condition, the data analysis is provided to predict and identify future diseases risk. Genetic testing is an item that wants to be used to help take better care of one's health and take preventive measures to stay healthy. (13 Cancers, 3 Dementia, 4 Cerebrovascular, 8 Metabolic Diseases)

## Oral Bacteria Genetic Test - Dr. Perio




Dr.Perio is a testing service that predicts oral health and body disease risk. The test provides effective prevention and treatment solution by quantitatively analyzing oral pathogenic strains(microorganisms) that cause periodontal disease, peri-implant disease, dental caries, bad breath, and systemic diseases using the M-QPCR technique. One out of five citizens suffering from periodontal disease, has been verified in the periodontal disease market with advanced preventive management systems.

## Dental Equipments/DCS Prevention Programs



iONEBIO Inc. sells a variety types of oral examination equipment and dental equipment. A surgical and general orokeeper to prevent cross-infection between patients and examiners. A phase contrast microscope that allows immediate observation of oral bacteria living through monitors such as PC and laptops and DCS, a preventive patient management program for efficient dental operation. We manufacture and sell a variety types of dental equipments that are easy to manage for patients.

## CashBrush



CashBrush is a win-win platform that allows consumers to record the number and time of brushing teeth and consumers receive cash rewards by connecting through an electric toothbrush and smartphone application to Bluetooth. Dentists have been requesting this platform to check their patients brushing their teeth after an implant treatment. Consumers receive rewards through brushing and they can purchase dental items and other products with the rewards accumulated on the app. Also, the company can create a lot of profitability by utilizing advertisements.

**The best opportunity to become  
a global corporate shareholder,  
ioneBIO Inc. is looking forward to your participation.**

Representative Number

Information/Inquiries | T: 031-360-1210 F: 031-360-1220

**Domestic business/  
investment inquiries**

Domestic Business Department  
070-8693-3941  
js.lee@ionebio.com

**Other stock related inquiries**

Management Planning Department  
031-360-1263  
sh.park@ionebio.com

**Inquiries related to overseas business**

Overseas Business/Marketing Department  
031-360-1210  
kh.kim@ionebio.com

**Chapter 3**

Investor Relations

**Benefits for Shareholders**

- Tax Benefits
- IPO / Plan of listing schedule
- Q&A





## Why should we invest in small and medium-sized companies (hidden hero) rather than large companies?

Small companies can **grow much faster** than big companies.

This is the reason why it can bring relatively **larger returns** to corporate investors than large corporations.

Small companies vs. Big companies	
Small companies(Hidden Heros)	Big companies
Excellent innovation and creativity by maintaining an appropriate scale	Slow creativity by striving to scale up
The best corporate culture than the largest	Conservative on new ideas
Specific technology in the field with high competitiveness	Business expansion to all sides rather than specialization




# 1

Investor Relations

## Tax Benefits

### Venture Business Investment Benefits

If you invest in a venture company within 5 years after **start-up** or a venture company within 3 years after conversion into a venture company and transfer it after 3 years from the date of investment, you can receive **tax-free benefits**.




Income deduction for each section of comprehensive income tax			
Standard of Assessment	Tax Rate	Health Insurance	Deduction
More than KRW 500 million	46.2%	6.7%	KRW 3.54 million
KRW 300~500 million	44.0%		KRW 2.54 million
KRW 150~300 million	41.8%		KRW 1.94 million
KRW 8,800~150 million	38.5%		KRW 1.49 million
KRW 4,600~8,800	26.4%		KRW 5.22 million

Comprehensive income tax income deduction, investment case of 30 million won			
Standard of Assessment	Total Deductible Tax Rate	Income Deduction Conversion Amount	Real Investment
More than KRW 500 million	52.90%	KRW <b>15.87</b> million	KRW 22.08 million
KRW 300~500 million	50.70%	KRW <b>15.21</b> million	KRW 16.44 million
KRW 150~300 million	48.50%	KRW <b>14.55</b> million	KRW 15.45 million
KRW 8,800~150 million	45.20%	KRW <b>13.56</b> million	KRW 14.79 million
KRW 4,600~8,800	33.10%	KRW <b>7.92</b> million	KRW 14.13 million

# 2

Investor Relations

## IPO / Plan Of Listing Schedule



※ The schedule may be changed depending on the company's business progress.

## Q&A that shareholders are curious about

### Q. What is the FDA/export status of the COVID-19 Test kit?

After exporting the Fast Infection Control system to the airport of Paraguay for the first time in the world, it is possible to check the results within an hour, love calls are coming from Paraguay's public hospitals, Indonesia, Peru, Mali, and Kyrgyzstan. The FDA has a request for additional clinical trials, so if a clinical result report is released after passing Dankook University's IRB review, the review will be completed after the FDA data is submitted, and a license will be issued.

### Q. What is the status of the alveolar bone treatment?

Alveolar bone treatment, a technology transferred received from Professor Min Byeong-Moo of the Seoul National University, graduate school of dentistry, has proven its remarkable performance in In vitro and In vivo experiments. In the future, if global clinical trials are conducted through new drug development projects in the future, the company's value will be further maximized. In particular, it has excellent alveolar bone resilience against periodontal disease bone loss, so it is highly scalable to various derivatives such as implant coatings, toothpastes, and gargles.

### Q. What is the progress of the oral cancer detection kit?

The oral cancer detection kit has been selected as a project to support innovative technology project for small and medium-sized companies and is currently in the process of research and development. In the future, prototypes may be released and clinical evaluation of new medical technologies may proceed. Since this kit is the first oral cancer detection kit in the global market as well as in South Korea, we are looking at an exclusive market of over \$80,000,000 in Korea and over \$20,000,000,000 in overseas markets.

### Q. In what progress is the of the 3D Intra oral scanner?

Currently, 3D oral scanners have already completed all product development last year, and only mass production and licenses remain. With the outbreak of the Corona crisis in early 2020, we had to concentrate all our personnel on the covid-19 test kit, and now we are preparing for mass production of 3D oral scanners that were delayed due to the stabilization of sales to some extent.

### Q. What is the IPO listing plan and schedule?

We are aiming to be listed through technological evaluation with our unrivaled diagnostic kit technology and alveolar bone treatments that show significant results. The ongoing overseas export of COVID-19 test kits and FICS(fast infection control system) at the airport is a great opportunity to secure a bridgehead for IONEBIO's global advancement. In the future, when launching various products around the world, it will make a great contribution and you can get a good evaluation in the technical evaluation.

### Q. What are your company's prospects and plans for the future? (Material for growth engine)

We have a plan to complete the technology transfer for the alveolar bone treatment. Then, IONEBIO will have a three core biotechnology resources (devices, diagnostics, medicines), including 3D oral scanners, oral cancer detection kits, and alveolar bone treatments. Therefore, it is stable enough to be incomparable to other bio companies and can exhibit a strong growth engine, and can make a great contribution to raising the stock value.



# Hidden Hero

**Our dreams with  
you are now to become reality**

Thank you.  
**iONEBIO Inc.**